Exelixis Inc.

NASDAQ: EXEL
Share price (8/13/25): $38.49
Market cap (8/13/25): $10.4 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Credit Agreements Filter

from 10-Q 67 pages Product Development and Commercialization Agreement Between Smithkline Beecham Corporation Doing Business as Glaxosmithkline and Exelixis, Inc. Dated as of October 28, 2002

from 10-Q 9 pages Eleventh Amendment to Loan and Security Agreement

from 10-Q 8 pages Tenth Amendment to Loan and Security Agreement

from 10-K 4 pages First Amendment to Loan and Security Agreement

from 8-K 5 pages Ninth Amendment to Loan and Security Agreement

from 10-Q 3 pages Fourth Amendment to the Loan and Security Agreement Between Smithkline Beecham Corporation D/B/a Glaxosmithkline and Exelixis, Inc. Effective October 28, 2002

from 8-K 6 pages Eighth Amendment to Loan and Security Agreement

from 8-K 7 pages Seventh Amendment to Loan and Security Agreement

from 10-K 6 pages Third Amendment to the Loan and Security Agreement Between Smithkline Beecham Corporation D/B/a Glaxosmithkline and Exelixis, Inc. Effective October 28, 2002

from 8-K 7 pages Loan Modification Agreement

from 10-Q 2 pages Loan Modification Agreement

from 10-Q ~50 pages Smithkline Loan & Security Agrmt